Article Text

Download PDFPDF
CASE REPORT
Monocytopenia in clozapine-induced agranulocytosis: insights into pathophysiology and treatment
  1. Rajvi Patel1,
  2. Ateaya Lima2,
  3. Christopher Burke2 and
  4. Mark Hoffman1
  1. 1 Monter Cancer Center-Division of Hematology Oncology, Northwell Health, Lake Success, New York, USA
  2. 2 Department of Psychiatry, Northwell Health, Queens, New York, USA
  1. Correspondence to Dr Mark Hoffman, mhoffma{at}northwell.edu

Abstract

A 26-year-old man with history of schizophrenia was admitted for neutropaenia. He was started on clozapine 3 months prior to admission. As a result he had weekly monitoring of his blood counts and on day of admission was noted to have an absolute neutrophil count (ANC) of 450 cells/μL. He was admitted for clozapine-induced agranulocytosis. Clozapine was held and the patient was started on granulocyte colony-stimulating factor (G-CSF) filgrastim and received two doses without any signs of ANC recovery. On further review, it was noted that the absolute monocyte count (AMC) was also low and tracked with the trend of ANC. We then theorised that the impact of clozapine was on a haematopoietic precursor (colony-forming unit granulocyte-macrophage, CFU-GM) which gives rise to both monocytic and myeloid lineages. Therefore, sargramostim GM-CSF was started. After two doses, the ANC and AMC started trending up and by the third dose, both counts had fully recovered. He was discharged from the hospital and there are no plans to rechallenge with clozapine. Thus, we demonstrate a case of monocytopenia accompanying clozapine-induced agranulocytosis with successful use of GM-CSF. At least in this case, the target of the clozapine injury appears to be the CFU-GM, explaining the rapid and full response to GM-CSF after lack of response to G-CSF.

  • haematology (drugs and medicines)
  • psychiatry (drugs and medicines)
  • haematology (incl blood transfusion)
  • medical management
  • malignant and benign haematology
View Full Text

Statistics from Altmetric.com

Footnotes

  • Patient consent for publication Obtained.

  • Contributors RP: conception, acquisition of data, analysis, drafting, revision, final approval; AL: drafting, final approval; CB: final approval; MH: conception, acquisition of data, analysis, drafting, revision, final approval.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.